Gene-level and SNP-level analysis identified marginally significant associations for FMO5 variation, representing an EHR-driven pharmacogenetics hypothesis for a potential novel mechanism for metformin biotransformation.
← all excerpts
Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis.
2
—
—
The sentences
While the FMO5 gene appeared to be of marginal significance in relation to glycemic response to metformin, our secondary hypothesis for the remaining FMO genes demonstrated no significance.